Results 11 to 20 of about 3,528 (147)

Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine [PDF]

Diagnostics, 2023
Objectives: In this prospective study, SARS-CoV−2 spike protein specific total immunoglobulin (Ig) levels were analyzed before and after BNT162 b2 mRNA booster vaccination in individuals previously administered with two doses of BBIBP-CorV vaccine in ...
Éva Rákóczi, Gusztáv Magócs, Sára Kovács, Béla Nagy, Gabriella Szűcs, Zoltán Szekanecz   +5 more
doaj   +3 more sources

Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals. [PDF]

PLoS Pathogens, 2023
BackgroundThis study aimed at evaluation and comparison of PastoCovac Plus protein-subunit vaccine in parallel with ChAdOx1-S (AstraZeneca) and BBIBP-CorV (Sinopharm) in primarily vaccinated volunteers with two doses of ChAdOx1-S or BBIBP-CorV.Materials ...
Sana Eybpoosh, Alireza Biglari, Rahim Sorouri, Fatemeh Ashrafian, Mona Sadat Larijani, Vicente Verez-Bencomo, Maria Eugenia Toledo-Romani, Carmen Valenzuela Silva, Mostafa Salehi-Vaziri, Sarah Dahmardeh, Delaram Doroud, Mohammad Banifazl, Ehsan Mostafavi, Anahita Bavand, Amitis Ramezani   +14 more
doaj   +3 more sources

Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease

Vaccines, 2022
Vaccination against coronavirus disease 2019 (COVID-19) has become an important public health solution. Developing a safe and effective vaccine against COVID-19 is a viable long-term solution to control the pandemic.
Linyi Chen, Qing-Bin Lu, Fuqiang Cui
exaly   +4 more sources

Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial

Vaccines, 2022
Purpose: This study was completed to assess the immunogenicity and safety of the FAKHRAVAC and BBIBP-CorV vaccines as a booster dose in the population with a history of receiving two doses of BBIBP-CorV vaccine.
Mohammadreza Ahi, Ahmad Karimi Rahjerdi, Kimiya Gohari   +2 more
exaly   +4 more sources

Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine

Vaccines, 2022
Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively evaluated globally due to waning immunity and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants.
Sitthichai Kanokudom, Ritthideach Yorsaeng, Sirapa Klinfueng   +2 more
exaly   +4 more sources

IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China

Vaccines, 2022
The purpose of this study was to preliminarily evaluate the immunogenicity and immune persistence of inactivated SARS-CoV-2 vaccines in PLWH in the real world.
Guang Zeng, Shuidong Feng, Xiaohui Wang   +2 more
exaly   +4 more sources

Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals [PDF]

Vaccine, 2023
BACKGROUND: Booster vaccine doses against SARS-CoV-2 have been advocated to address evidence of waning immunity, breakthrough infection, and the emergence of immune-evasive variants. A heterologous prime-boost vaccine strategy may offer advantages over a
Saad I Mallah, Abdulla Alawadhi, Pearl Wasif   +2 more
exaly   +4 more sources

A real-world study of BBIBP-CorV vaccine effectiveness in a Sri Lanka rural province [PDF]

Heliyon
Objective: Real-world studies assessing the effectiveness of the BBIBP-CorV vaccine in low and middle-income countries are limited. We evaluated the BBIBP-CorV vaccine's effectiveness in reducing COVID-19 symptomatic disease, hospitalisation, severe ...
Yunkai Yang, Lanka Wijekoon, Thilina Rathnasekara   +2 more
exaly   +4 more sources

Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial [PDF]

BMC Medicine
Background The immunity induced by primary vaccination is effective against COVID-19; however, booster vaccines are needed to maintain vaccine-induced immunity and improve protection against emerging variants.
Saeed Erfanpoor, Seyed Reza Banihashemi, Ladan Mokhbaeralsafa, Saeed Kalantari, Ali Es-haghi, Mojtaba Nofeli, Ali Rezaei Mokarram, Fariba Sadeghi, Monireh Hajimoradi, Seyad Hossein Razaz, Maryam Taghdiri, Mohsen Lotfi, Akbar Khorasani, Akram Ansarifar, Safdar Masoumi, Arash Mohazzab, Sara Filsoof, Vahideh Mohseni, Masoumeh Shahsavan, Niloufar Gharavi, Seyed Amin Setarehdan, Mohammad Hasan Rabiee, Mohammad Hossein Fallah Mehrabadi, Masoud Solaymani-Dodaran   +23 more
doaj   +3 more sources

The Efficacy and Safety of Heterologous Immunization with Pfizer-BioNTech (Pfizer) to Individuals Who Have Completed A Primary Vaccination Schedule with Sinopharm (BBibp-CorV)

Journal of Pure and Applied Microbiology, 2023
The aim of this study was to examine the effectiveness and potential adverse reactions when providing a different Pfizer-BioNTech booster shot to 235 volunteers who had previously received the BBIBP-CorV Sinopharm primary vaccination series.
Nawfal R. Hussein, Warveen L. Abdulkareem, Narin A. Rasheed, Mohammed Rashid Ameen   +3 more
doaj   +3 more sources